AG1 (Athletic Greens)

• Closing documented vitamin and mineral gaps (AG1-reported, plausible)
• Daily foundational nutrition insurance for inconsistent eaters
• Travel or on-the-road nutrient convenience
• A once-daily routine anchor for gut and energy (marketed, weak evidence)
• NSF Certified for Sport option for tested athletes wanting a greens/vitamin base

AG1 (formerly Athletic Greens, rebranded to AG1 around 2022) is the foundational daily greens-and-vitamin powder from Athletic Greens Limited, the New Zealand-headquartered direct-to-consumer supplement company founded in 2010 by Chris Ashenden. The product is positioned as a "75-ingredient comprehensive nutrition foundation" combining multiple ingredient categories in a single daily serving: a multivitamin baseline (most vitamins and minerals at 100-300% RDA depending on nutrient), a greens blend (spirulina, chlorella, wheatgrass, barley grass, alfalfa, broccoli, kale, spinach, others), an antioxidant fruit blend (acerola, blueberry, apple, papaya, pineapple, others), an adaptogenic herb blend (ashwagandha, rhodiola, eleuthero, milk thistle, dandelion at modest doses), a digestive enzyme blend (amylase, protease, lipase, bromelain, papain, others), a probiotic blend (typically Lactobacillus acidophilus and Bifidobacterium bifidum at modest 1-7.2 billion CFU per serving range), prebiotic fibers (inulin from chicory root), and various functional mushroom and botanical extracts. The substantial 75+ ingredient density (substantially more than Bloom's ~30 ingredients but less than Huel Daily Greens' 91 ingredients) creates impression of comprehensive coverage; the dose of any one functional ingredient is typically substantially below the studied therapeutic single-supplement dose for that constituent alone. Approximately 12g per serving, substantially larger than Bloom's ~7g or Live It Up's smaller servings, providing modestly more total ingredient mass for the multi-blend formulation. The pharmacological mechanism profile is essentially aggregate, each ingredient (when included at appropriate doses) provides its own pharmacology, with the combination providing comprehensive but typically modest-dose multi-nutrient support. The substantial vitamin and mineral component provides foundational multivitamin coverage; the greens blend provides modest polyphenol, chlorophyll, and trace nutrient contribution; the antioxidant fruit blend provides modest polyphenol and vitamin C contribution; the digestive enzymes provide modest gastric/intestinal enzymatic activity; the probiotics provide modest microbiome contribution (substantially lower-dose than dedicated probiotic products like Seed DS-01 at 53.6 billion AFU or Visbiome at 450 billion CFU); the adaptogenic blend provides modest ashwagandha (typically 50-100mg vs therapeutic 300-600mg KSM-66 or Sensoril), rhodiola (typically 50-100mg vs therapeutic 200-400mg), and eleuthero contributions at substantially sub-therapeutic individual doses. The substantial total ingredient count creates impression of comprehensive support; the modest per-ingredient dose limits clinically meaningful pharmacological effect for most individual constituents at their AG1 inclusion doses. The product functions reasonably as a "convenient multivitamin-plus-modest-multi-nutrient-bridge" supplementation framework, not as a substitute for targeted clinical supplementation at therapeutic doses. The AG1 commercial framework defined the modern Class C single-brand multi-ingredient supplement category through the 2010s-2020s. The substantial early commercial development period (2010-2018) emphasized direct-to-consumer sales through Chris Ashenden's entrepreneur network and early adopter health communities; the substantial podcast advertising era (2018-present) established AG1 as among the most-advertised supplement brands in the long-form podcast economy. The substantial advertising investment in Tim Ferriss's podcast, Joe Rogan Experience, Lex Fridman Podcast, Andrew Huberman's Huberman Lab, Peter Attia's The Drive, and many other major health/longevity-focused podcasts created the substantial brand awareness expansion that defined the modern DTC supplement marketing model. The substantial Andrew Huberman partnership (Huberman as paid spokesperson and substantial brand association) was substantially scrutinized in 2024 reporting regarding podcast supplement endorsement transparency and AG1's aggressive marketing positioning. The substantial $1.2 billion valuation reportedly achieved through Goldman Sachs and other institutional investor partnerships in 2022 established AG1 among the highest-valued supplement DTC brands globally. The substantial third-party testing positioning distinguishes AG1 within the multi-ingredient greens powder category, AG1 holds NSF Certified for Sport certification (substantial pharmaceutical-grade testing framework that screens for over 270 substances banned by major sports organizations) and various additional certifications. This substantial testing positioning provides reasonable consumer assurance versus broader greens powder category where heavy metal contamination concerns and proprietary blend opacity are substantial issues. The substantial $79-99/month subscription pricing (substantially higher than Bloom's $30-40, Live It Up's $40-50, or Huel Daily Greens' $50-70) reflects substantial premium clinical positioning; cost-per-equivalent-nutrient analysis demonstrates comparable nutrition is available from separate supplements at roughly one-third the AG1 price.

AG1 is dosed at 1 scoop (~12g) daily mixed in 8oz of cold water, ideally consumed in the morning, often before breakfast or as part of morning routine. The substantial subscription model ($79/month) provides automatic monthly delivery; one-time purchase at $99+ provides flexibility without commitment. Take consistently, multi-ingredient supplementation works through sustained dietary bridge framework rather than acute pharmacological effect; missing doses occasionally is unlikely to substantially affect outcomes. Storage: room temperature with substantial moisture protection (closed container, dry environment) maintains formulation stability. The substantial 12g serving size provides substantially more total ingredient mass than Bloom's ~7g or Live It Up's smaller servings; the modest per-ingredient dosing across the 75+ ingredient blend limits clinically meaningful pharmacological effect for individual constituents. The substantial NSF Certified for Sport certification provides substantial consumer assurance distinct from broader greens powder category testing limitations. Take with or without food, absorption is reasonable either way; many users prefer morning dosing as part of routine breakfast or pre-workout consumption. AG1 is not designed for specific therapeutic dose individual nutrient applications, users seeking targeted clinical supplementation (specific vitamin D3 dose, magnesium dose, omega-3 dose, therapeutic adaptogen dose, dedicated probiotic dose) should consider standalone supplementation in addition to or instead of multi-ingredient greens powders. The substantial proprietary blend disclosure pattern means users cannot verify per-ingredient dosing for several blends; this is a substantial pharmacological transparency limitation versus standalone supplementation. The substantial price premium versus competitors ($79-99/month vs Bloom $30-40, Live It Up $40-50, Huel $50-70) reflects substantial premium clinical positioning; cost-per-equivalent-nutrient analysis demonstrates comparable nutrition available from separate supplements at roughly one-third the AG1 price. Reasonable framework: AG1 as premium comprehensive multi-nutrient supplementation bridge for users prioritizing convenience and premium positioning; alternatives like Bloom or Huel as accessible mass-market alternatives; standalone targeted supplementation for users seeking specific therapeutic dosing. The pregnancy and lactation contexts warrant specialist coordination given the multi-ingredient complexity, dedicated prenatal vitamin supplementation generally preferred. The pediatric contexts warrant specialist coordination given the unclear pediatric safety profile of various ingredients (the adaptogenic herbs particularly). The drug interaction profile is complex given the multi-ingredient nature, coordinate with prescribing physicians for users on warfarin (substantial vitamin K interaction), thyroid medications (calcium and iron absorption interactions), immunosuppressants (adaptogen and herbal content interactions), or other medications with substantial supplement interaction profiles. Companion product framework: AG1 Vitamin D3 + K2 and AG1 Omega-3 add-ons provide therapeutic dosing of specific nutrients for users seeking AG1 brand consistency across product portfolio; reasonable consumer choice though substantially more expensive than generic standalone alternatives.

Standard daily dose

1 scoop (~12g) daily

Mixing

8oz cold water (or smoothies if preferred)

Timing

Morning; often pre-breakfast

Serving size vs competitors

~12g AG1 vs ~7g Bloom vs smaller Live It Up

Price point subscription

$79/month

Price point one-time

$99+ retail

Total ingredients

75+ ingredients across multiple blends

Vitamin K content

~200% RDA (warfarin interaction concern)

• AG1 Daily Greens Powder (Subscription)

  Rating: gold

  The flagship AG1 daily greens powder, 75+ ingredients including greens, antioxidant fruit blend, adaptogenic herbs, digestive enzymes, probiotics, prebiotics, and comprehensive multivitamin baseline. Approximately 12g per serving. Subscription pricing at $79/month with substantial discount versus one-time purchase at $99+. NSF Certified for Sport. Travel pack option included with subscription. Foundational flagship product.

• AG1 Travel Packs

  Rating: gold

  Single-serving travel-friendly individual packets for travel and convenience use. Substantial mass-market consumer positioning pioneered the travel packet category subsequently adopted by Bloom and other competitors. Convenient portion control; included with subscription orders.

• AG1 Vitamin D3 + K2 Add-On

  Rating: gold

  Companion vitamin D3 plus K2 supplement marketed as AG1 add-on for users seeking higher vitamin D3 dosing than AG1 baseline provides. Reasonable companion supplementation for users with vitamin D deficiency or seeking therapeutic D3 dosing. Substantial cross-promotional positioning.

• AG1 Omega-3 Fish Oil Add-On

  Rating: gold

  Companion fish oil supplement marketed as AG1 add-on for users seeking omega-3 EPA/DHA supplementation. Reasonable companion supplementation; substantial cross-promotional positioning.

• AG1 One-Time Purchase (Non-Subscription)

  Rating: good

  One-time purchase at $99+ price point (substantially higher than $79/month subscription pricing). Reasonable consumer option without subscription commitment; subscription pricing provides substantial price advantage.

• AG1 Multi-Container Bundle

  Rating: good

  Multi-container bundle pricing for users committing to longer supply duration. Substantial subscription/bundle savings; reasonable consumer option for established AG1 users.

• Generic Comprehensive Daily Greens Alternative

  Rating: caution

  Numerous lower-priced multi-ingredient greens powder alternatives exist (Bloom $30-40, Live It Up $40-50, Huel Daily Greens $50-70, Garden of Life Perfect Food, KOS Organic Superfood, Amazing Grass Greens Blend, many others). Substantial price differential versus AG1; substantial third-party testing variation across competitors. Reasonable consumer choice based on price/quality preferences.

• Standalone Targeted Supplementation (Multi-Component)

  Rating: gold

  For users seeking therapeutic dosing of specific nutrients (vitamin D3, magnesium, omega-3, ashwagandha, rhodiola, dedicated probiotic, etc.), separate standalone supplementation provides substantially better dose precision at substantially lower total cost than AG1 multi-ingredient framework. Reasonable approach for users prioritizing therapeutic dosing over comprehensive convenience.

• Whole Foods Dietary Vegetable Intake

  Rating: gold

  Substantial whole foods vegetable consumption (2-3+ cups daily per USDA guidelines) provides foundational nutritional intake that powdered greens concentrates cannot fully replicate, substantial fiber, water content, broader phytochemical complement, satiety and chewing mechanisms. Reasonable foundational nutritional approach; greens powders provide convenient dietary bridge but not substitute for whole foods vegetable intake.

• Adults with low dietary vegetable intake seeking nutritional bridge

  Strength of evidence for this group: modest

  Approximately 90% of Americans don't meet daily vegetable intake recommendations. Greens powder supplementation including AG1 provides convenient dietary bridge; whether powdered concentrates provide equivalent nutritional benefit to whole vegetable consumption is substantially debated. Reasonable supplementation framework; not substitute for dietary vegetable intake.

• Adults seeking premium clinically-positioned greens supplementation

  Strength of evidence for this group: modest

  AG1's substantial premium positioning ($79-99/month) and substantial NSF Certified for Sport third-party testing investment provides substantial consumer assurance versus broader greens powder category testing limitations. Reasonable framework for users prioritizing premium clinical positioning and willing to pay substantial price premium.

• WADA-tested competitive athletes

  Strength of evidence for this group: modest

  AG1's NSF Certified for Sport certification provides substantial pharmaceutical-grade testing assurance distinct from broader greens powder category. Reasonable supplementation framework for WADA-tested athletes seeking comprehensive multi-nutrient supplementation with verified contamination screening. Among the substantial advantages of AG1 versus broader competitor positioning that lacks comparable testing certification.

• Adults seeking convenience-focused multi-nutrient daily supplementation

  Strength of evidence for this group: modest

  The substantial 75+ ingredient single-scoop daily format provides substantial convenience advantage versus multiple standalone supplements. Reasonable framework for users prioritizing convenience over therapeutic dose precision or cost optimization. The substantial subscription model provides automatic monthly delivery convenience.

• Adults prioritizing comprehensive ingredient density

  Strength of evidence for this group: cautious

  AG1's 75+ ingredient formulation provides comprehensive impression; per-ingredient dosing is substantially limited across the 12g serving. Users prioritizing single-ingredient therapeutic dosing should consider standalone supplementation; users prioritizing comprehensive multi-nutrient bridge should consider AG1 or alternatives. The substantial ingredient density may not provide proportional clinical advantage versus dose-optimized alternatives.

• Adults willing to pay substantial price premium

  Strength of evidence for this group: cautious

  AG1's $79-99/month pricing is substantially higher than Bloom ($30-40), Live It Up ($40-50), Huel Daily Greens ($50-70), or generic alternatives. Cost-per-equivalent-nutrient analysis demonstrates comparable nutrition available at roughly one-third the AG1 price through separate standalone supplements. Reasonable consumer choice for users prioritizing brand positioning and convenience; substantial cost-effectiveness limitation for users prioritizing value.

• Pregnancy and lactation

  Strength of evidence for this group: cautious

  The multi-ingredient nature creates substantial complexity for pregnancy supplementation safety assessment. The adaptogenic herbs (ashwagandha, rhodiola, eleuthero) typically not recommended during pregnancy; some other ingredients may have unclear pregnancy safety. Specialist OB-GYN coordination essential; dedicated prenatal vitamin supplementation generally preferred over multi-ingredient greens powders during pregnancy.

• Adults on warfarin or anticoagulants

  Strength of evidence for this group: cautious

  AG1 vitamin K content is substantial (approximately 200% RDA from leafy greens content), substantial warfarin INR interaction concern. Other ingredients with mild antiplatelet effects (various polyphenols, fish oil if added with companion supplements) compound the interaction profile. Coordinate with anticoagulation management; substantial consistency in supplementation timing matters for INR stability if AG1 continued in warfarin users.

• Users seeking established brand-specific clinical evidence

  Strength of evidence for this group: cautious

  AG1 lacks substantial brand-specific clinical evidence (single small internal open-label study). Ingredient-level evidence supports modest individual benefits; brand-specific clinical research is generally limited. Users seeking evidence-based supplementation should evaluate individual ingredient evidence rather than relying on brand positioning. The substantial NSF Certified for Sport certification provides substantial quality framework distinct from brand-specific clinical evidence.

• Adults with diabetes or carbohydrate-restricted diets

  Strength of evidence for this group: modest

  AG1 has modest natural sugar content from fruit and vegetable ingredients (typically <1g sugar per serving); substantially lower carbohydrate burden than flavored Bloom varieties. Reasonable supplementation framework for users with diabetes or strict carbohydrate restriction; verify per-serving carbohydrate content matches consumer expectations.

• Pediatric use

  Strength of evidence for this group: cautious

  Multi-ingredient greens powders generally not designed for pediatric supplementation. The adaptogenic herbs and various other ingredients have unclear pediatric safety; pediatric multivitamin formulations preferred. AG1 has marketed adult positioning; specialist coordination for pediatric supplementation contexts.

• Users seeking dedicated probiotic supplementation

  Strength of evidence for this group: cautious

  AG1 probiotic content (typically 1-7.2 billion CFU) is substantially below therapeutic probiotic dose ranges. Users seeking substantial probiotic supplementation should consider dedicated probiotic products (Seed DS-01 at 53.6 billion AFU, Visbiome at 450 billion CFU, single-strain dedicated alternatives) rather than relying on AG1 probiotic content.

• Users seeking therapeutic adaptogen effects

  Strength of evidence for this group: cautious

  AG1 adaptogen content (ashwagandha typically 50-100mg, rhodiola typically 50-100mg, eleuthero modest) is substantially below therapeutic single-supplement adaptogen ranges (KSM-66 or Sensoril ashwagandha 300-600mg; rhodiola 200-400mg). Users seeking therapeutic adaptogen effects should use dedicated standardized adaptogen products in addition to or instead of AG1 multi-ingredient framework.

• Established functional bowel disorders

  Strength of evidence for this group: cautious

  The substantial fiber content, digestive enzyme content, and probiotic content of AG1 may produce GI effects (bloating, gas, altered bowel habits) particularly with initial supplementation. Generally well-tolerated with adjustment; users with established IBS, IBD, or other functional bowel disorders should consider specialist gastroenterology coordination.

• Users with thyroid medications

  Strength of evidence for this group: cautious

  AG1 calcium and iron content may modestly reduce levothyroxine absorption; substantial mineral content across the 75+ ingredient formulation creates substantial absorption interaction context. Take levothyroxine first thing in morning on empty stomach; AG1 consumption later in day (mid-morning or later) avoids the substantial absorption interaction window.

• Standalone Targeted Supplementation

  Interaction: synergy

  For users seeking therapeutic dosing of specific nutrients (vitamin D3, magnesium, omega-3, ashwagandha at therapeutic doses, dedicated probiotic, etc.), standalone supplementation in addition to or instead of AG1 multi-ingredient framework provides substantially better dose precision at substantially lower total cost. Reasonable combination of AG1 as multi-nutrient bridge plus standalone supplementation for specific therapeutic dosing. AG1's own companion products (D3+K2, Omega-3 fish oil) provide AG1-brand-consistent companion supplementation.

• Dedicated Probiotic Products (Seed DS-01 and others)

  Interaction: synergy

  AG1's probiotic content is modest dose relative to dedicated probiotic products (Seed DS-01 at 53.6 billion AFU across 24 strains; Visbiome at 450 billion CFU). Users seeking substantial probiotic supplementation should consider dedicated probiotic products rather than relying on greens powder probiotic content. Reasonable complementary framework using AG1 for multi-nutrient bridge + Seed DS-01 for dedicated probiotic supplementation.

• Dedicated Adaptogen Standalone (Ashwagandha, Rhodiola, etc.)

  Interaction: synergy

  AG1's adaptogenic herbs (ashwagandha 50-100mg, rhodiola 50-100mg) are substantially modest doses relative to dedicated standalone adaptogen products. Users seeking therapeutic adaptogen dosing should consider standalone supplementation (KSM-66 or Sensoril ashwagandha at 300-600mg; rhodiola at 200-400mg) rather than relying on greens powder adaptogen content.

• AG1 Vitamin D3 + K2 Add-On

  Interaction: synergy

  AG1 baseline vitamin D3 content (typically modest dose) may not provide therapeutic dosing for users with vitamin D deficiency or seeking higher dosing for autoimmune or bone health applications. AG1's Vitamin D3 + K2 companion product provides therapeutic D3 dosing within AG1 brand-consistent framework. Reasonable companion supplementation though substantially more expensive than generic D3 standalone alternatives.

• AG1 Omega-3 Fish Oil Add-On

  Interaction: synergy

  AG1 baseline formulation does not include substantial omega-3 EPA/DHA content. AG1's Omega-3 fish oil companion product provides EPA/DHA supplementation within AG1 brand-consistent framework. Reasonable companion supplementation though substantially more expensive than generic fish oil standalone alternatives.

• Warfarin and Anticoagulants

  Interaction: caution

  AG1 vitamin K content (~200% RDA from leafy greens) is substantial warfarin INR interaction concern; other ingredients with mild antiplatelet effects compound the interaction profile. Coordinate with anticoagulation management; substantial consistency in AG1 supplementation timing matters for warfarin INR stability if continued.

• Thyroid Medications (Levothyroxine)

  Interaction: caution

  AG1 calcium and iron content may modestly reduce levothyroxine absorption; substantial mineral content across 75+ ingredient formulation creates substantial absorption interaction. Take levothyroxine first thing in morning on empty stomach; AG1 consumption later in day (mid-morning or later) avoids substantial absorption interaction window.

• Immunosuppressants (Cyclosporine, Tacrolimus, Methotrexate)

  Interaction: caution

  AG1 adaptogenic herbs (ashwagandha, rhodiola, eleuthero) and various other ingredients may have modest immunomodulatory effects. Coordinate with prescribing physicians; specialist coordination for transplant medicine or autoimmune disease contexts.

• Pregnancy and Lactation

  Interaction: caution

  Multi-ingredient nature with ashwagandha, rhodiola, eleuthero, and various other ingredients with unclear pregnancy safety creates substantial pregnancy coordination context. Dedicated prenatal vitamin supplementation generally preferred during pregnancy and lactation.

• Other Multi-Ingredient Greens Powders

  Interaction: caution

  Combining multiple multi-ingredient greens powders (AG1 + Bloom + Huel Daily Greens, etc.) produces substantial ingredient duplication without proportional benefit. Reasonable choice between multi-ingredient products rather than combination supplementation.

• Dedicated Multivitamin Supplementation

  Interaction: caution

  Combining AG1 with comprehensive multivitamin supplementation produces substantial ingredient overlap (AG1 includes comprehensive multivitamin baseline). Verify total dose accumulation across products; substantial vitamin and mineral dose accumulation possible if multiple products combined.

• Coffee and Caffeine

  Interaction: caution

  AG1 marketing has positioned the product as substantial morning routine companion; substantial caffeine consumption alongside AG1 is common. No substantial direct interaction concern; the substantial adaptogenic content (rhodiola particularly) may modestly modulate caffeine response.

Look for: NSF Certified for Sport certification (substantial pharmaceutical-grade third-party testing); explicit per-ingredient dose disclosure where available (AG1 publishes substantial ingredient transparency though substantial proprietary blends remain); appropriate serving size for intended use; reasonable subscription/retail purchase channel through AG1 direct-to-consumer or authorized retail; substantial brand reputation and review consistency. Avoid: substantial marketing claims that exceed evidence base; reliance on greens powder for therapeutic-dose individual nutrient supplementation (use standalone supplementation for specific therapeutic dosing); combination with multiple other multi-ingredient greens powders (ingredient duplication without proportional benefit); unverified third-party sellers on marketplaces where authenticity and freshness cannot be verified.

Athletic Greens was founded in 2010 by Chris Ashenden in New Zealand. Ashenden's substantial founding narrative emphasized personal GI health challenges that motivated comprehensive multi-ingredient supplementation framework, substantial entrepreneurial framework integrating personal health context with comprehensive nutritional supplementation. The initial product launch focused on comprehensive daily greens-and-vitamin powder positioned as substantial dietary bridge for users with limited dietary vegetable intake. The substantial New Zealand brand heritage provided distinctive consumer market positioning. The substantial early commercial development era developed substantially through 2010-2018 with primarily entrepreneur-network and early-adopter health community direct-to-consumer sales. The substantial brand identity emphasized comprehensive nutrition framework, premium clinical positioning, and substantial third-party testing investment (including substantial NSF Certified for Sport certification investment). The substantial brand differentiation versus generic greens powder competitors emphasized substantial premium positioning and substantial quality framework. The substantial podcast advertising era developed substantially through 2018-present. The substantial advertising investment in Tim Ferriss's podcast, Joe Rogan Experience, Lex Fridman Podcast, Andrew Huberman's Huberman Lab, Peter Attia's The Drive, and many other major health/longevity-focused podcasts established AG1 as among the most-advertised supplement brands in the long-form podcast economy. The substantial advertising investment shaped the broader DTC supplement marketing model, substantial podcast economy investment subsequently emulated by Bloom, Huel, Seed Health, and many other DTC supplement competitors. The substantial $5 trial subscription model became among the foundational DTC supplement marketing approaches. The Andrew Huberman partnership era developed substantially through 2020-2024 with Andrew Huberman as substantial AG1 spokesperson and substantial brand association with the science-positioning longevity podcast economy. The substantial partnership scrutiny in 2024 New York Magazine and other publication reporting examined the substantial podcast supplement endorsement framework, transparency disclosures, and AG1's marketing positioning. The 2024 reporting context represented substantial M-02 financial-stakeholder dynamics in the modern wellness podcast economy. The AG1 rebrand era developed substantially through 2022 with the substantial rebrand from "Athletic Greens" to "AG1" reflecting substantial brand evolution toward more streamlined consumer positioning. The substantial brand framework emphasizes the "75-ingredient comprehensive nutrition foundation" positioning as foundational category framework. The substantial institutional investment era developed substantially through 2022 with the reported $1.2 billion valuation through Goldman Sachs and other institutional investor partnerships. The substantial valuation established AG1 among the highest-valued supplement DTC brands globally, substantial venture capital and institutional capital validation of the multi-ingredient single-brand supplement model. The substantial valuation also positioned AG1 for potential IPO, acquisition, or continued private growth trajectories. The substantial product portfolio expansion era added AG1 Vitamin D3 + K2 add-on, AG1 Omega-3 fish oil add-on, AG1 Travel Packs, and various other category extensions. The substantial brand ecosystem positioning provides multiple consumer touchpoints within the AG1 framework. The modern category positioning has matured substantially through the 2020s with AG1 emerging as among the most-recognized greens powders globally, particularly in the premium clinical-positioning segment. The substantial category bifurcation between premium clinical-positioned greens powders (AG1) and mass-market accessible alternatives (Bloom, others) represents substantial market segmentation. The substantial influence on the broader DTC supplement marketing industry has been substantial, the AG1 model has substantially shaped the consumer wellness supplement category through the 2020s. The substantial competitive context within the Class C single-brand multi-ingredient category has matured substantially through the 2020s with substantial Bloom (Mari Llewellyn 2019 founding, Nestlé Health Science 2024 acquisition), Huel Daily Greens (UK 2023 launch), Live It Up (2023-2024 newer entrant), Seed DS-01 (Seed Health 2017 founding, probiotic synbiotic positioning), and many other competitors. The substantial category framework has evolved through the 2020s with substantial market segmentation between premium clinical positioning (AG1, Seed DS-01) and accessible mass-market alternatives (Bloom, Huel, Live It Up). The substantial regulatory framework includes FDA scrutiny of supplement marketing claims (the substantial FDA and FTC scrutiny of supplement marketing claims affects the broader DTC supplement category) and substantial state-level regulatory frameworks. The continued evolution of supplement regulation continues to shape the broader category framework. The substantial Andrew Huberman partnership scrutiny in 2024 reporting represents substantial broader podcast economy supplement endorsement scrutiny affecting category evaluation.

1. 2010Athletic Greens founded by Chris Ashenden in New Zealand
2. 2010-2018Early commercial development; entrepreneur-network and early-adopter sales
3. 2018-presentSubstantial podcast advertising era foundational expansion
4. 2020-2024Andrew Huberman partnership era
5. 2022Rebrand from "Athletic Greens" to "AG1"
6. 2022Goldman Sachs and institutional investor partnerships; reported $1.2B valuation
7. 2022-2024Product portfolio expansion (D3+K2, Omega-3, Travel Packs)
8. 2024Andrew Huberman partnership scrutiny in NY Magazine and other reporting
9. 2024Bloom Nestlé Health Science acquisition; comparable category validation
10. 2020sEstablished Class C premium category leader position

• Whether the substantial $79-99/month pricing premium versus competitors (Bloom $30-40, Huel $50-70, Live It Up $40-50) sustains as the category matures and substantial alternatives provide comparable nutritional positioning at substantially lower cost.
• Whether the substantial podcast advertising economy supplement endorsement framework will sustain or face substantial regulatory scrutiny following 2024 reporting on Andrew Huberman partnership and broader podcast economy transparency.
• Whether AG1 will pursue substantial brand-specific clinical trial investment beyond the single internal open-label study, or continue relying on ingredient-level evidence aggregation typical of the category.
• Whether AG1's substantial third-party testing positioning (NSF Certified for Sport) will continue to provide substantial competitive advantage versus competitor product positioning, or whether broader category will adopt comparable testing frameworks.
• Whether the substantial Goldman Sachs and institutional investor partnership trajectory will lead to potential IPO, acquisition by major pharma (following Bloom's 2024 Nestlé Health Science acquisition precedent), or continued private growth.
• Whether the substantial proprietary blend disclosure patterns will face regulatory pressure toward greater ingredient transparency.
• Whether AG1's substantial 12g serving size and 75+ ingredient density produces clinically meaningful advantages versus competitor formulations with different serving sizes and ingredient counts.
• Whether the substantial Andrew Huberman partnership reconfiguration following 2024 reporting affects substantial brand association with the science-positioning longevity podcast economy.
• How best to position AG1 within the broader Class C single-brand multi-ingredient category, substantial premium positioning vs. accessible mass-market competitors; substantial direct-to-consumer focus vs. mass-market retail expansion; substantial third-party testing positioning vs. category-broad testing limitations.
• Whether the substantial cost-per-nutrient analysis critique (comparable nutrition available at ~1/3 the AG1 price through separate standalone supplementation) will substantially affect consumer evaluation and category positioning over time.
• Whether substantial mass-market retail expansion (following Bloom's strategy) is in AG1's future or whether DTC-focused premium positioning is sustainable long-term.
• How substantial regulatory scrutiny of supplement marketing claims (FDA, FTC) affects AG1's positioning over time.

Direct-to-consumer through Athletic Greens / AG1 (drinkag1.com or athleticgreens.com) as the primary distribution channel. Legal under DSHEA in the United States and equivalent supplement regulations in most jurisdictions. Not on WADA prohibited list; NSF Certified for Sport certification provides substantial assurance for WADA-tested athletes. AG1 has expanded selectively to limited retail through specialty health/wellness channels but maintains substantial DTC focus contrasting with Bloom's mass-market retail expansion (Target, Walmart, CVS strategy). International availability includes US, Canada, UK, Australia, New Zealand, and select international markets through AG1 shipping framework. Pricing: $79/month subscription provides 30-serving monthly delivery with substantial subscription discount versus one-time purchase at $99+; multi-container bundle pricing provides additional savings for users committing to longer supply duration. The substantial subscription model includes travel pack inclusion and substantial customer service infrastructure. The substantial Goldman Sachs and institutional investor partnerships established AG1 among the highest-valued supplement DTC brands globally with reported $1.2B+ valuation through 2022 funding rounds. The substantial NSF Certified for Sport certification provides substantial pharmaceutical-grade testing assurance. Production sourcing involves multiple agricultural sources for the 75+ ingredients with substantial supply chain complexity. Specific sourcing transparency varies by ingredient, the substantial NSF Certified for Sport framework provides substantial contamination testing assurance. The substantial podcast advertising investment in Tim Ferriss, Joe Rogan, Lex Fridman, Andrew Huberman, Peter Attia, and many other major health/longevity-focused podcasts established AG1 as among the most-advertised supplement brands in the long-form podcast economy. The substantial Andrew Huberman partnership scrutiny in 2024 reporting represents substantial M-02 financial-stakeholder analysis context affecting the broader podcast supplement endorsement framework. The substantial brand positioning emphasizes premium clinical credibility versus accessible mass-market alternatives. The substantial 90-day money-back guarantee provides reasonable consumer trial framework.

Status current as of July 2026. Regulatory positions change, sometimes quickly.

Class

Single-brand multi-ingredient daily greens powder (foundational Class C)

Brand

Athletic Greens / AG1 (rebrand 2022)

Founder

Chris Ashenden (2010)

Country of origin

New Zealand

Standard dose

1 scoop (~12g) daily

Total ingredients

75+ across multiple blends

What follows is unfinished work on our side, not a finding about AG1 (Athletic Greens). A short entry is not a safe entry.

• Cost and market. We have not documented what it sells for or who sells it.
• Supply chain. We have not mapped where it is made.
• Who uses it. We have not documented the user groups.
• What could change. No forward-looking summary yet.
• How it compares. We have not set it against the alternatives.
• Children and teenagers. We have not checked what is known about younger people.
• Where we land. We have not taken a position on this yet.